Adjuvant Pembrolizumab Continues to Provide Survival Benefit

Pembrolizumab led to sustained improvements in recurrence-free survival and distant metastasis-free vs placebo as adjuvant therapy in patients with resected stage IIB or IIC melanoma

Related Keywords

Astellas Pharma , Immatics Incyte , Crown Bioscience , Jason Luke , Immunocore Incyte , Pembrolizumab Keytruda , Trex Bio , Codiak Biosciences , Bristol Myers Squibb , Serono , Novartis , Pfizer , Hillman Cancer Center , Cancer Immunotherapeutic Center , Gilead Sciences , Immunotherapy Program , Cstone Pharmaceuticals , Tizona Therapeutics Inc , Division Of Hematology Oncology , Checkmate Pharmaceuticals , Corvus Pharmaceuticals , Genentech , Bright Peak Therapeutics , Day One Therapeutics , Endeavor Biomedicines , Flame Biosciences , Hotspot Therapeutics , Inzen Therapeutics , Partner Therapeutics , Reflexion Medical , Ribon Therapeutics , Rubius Therapeutics , Silicon Therapeutics , Tempest Therapeutics , Werewolf Therapeutics , Xilio Therapeutics , Array Biopharma , Ikena Oncology , Moderna Therapeutics , Scholar Rock , Tizona Therapeutics , Trishula Therapeutics , Actym Therapeutics , Arch Oncology , Kanaph Therapeutics , Mavu Pharmaceutical , Melanoma , Advanced Melanoma , Skin Cancer , Pd L1 Inhibitor , Immunotherapy , Immune Checkpoint Inhibitor , Pici , Pasco , Asco Annual Meeting , Pembrolizumab , Adjuvant ,